VX-984

• Description :

  VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks) . VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium[1][2][3].

• Product Name Alternative :

  M9831

• UNSPSC :

  12352005

• Target :

  DNA-PK

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  99.47

• Solubility :

  DMSO : 10 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC=NC2=C([C@H](C)CNC3=CC(C4=C([2H])N=C(C)N=C4[2H])=NC=N3)C=CC=C12)NC

• Molecular Formula :

  C23H21D2N7O

• Molecular Weight :

  415.49

• References & Citations :

  [1]Timme CR, et al. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts. Mol Cancer Ther. 2018 Jun;17 (6) :1207-1216.|[2]Khan AJ, et al. VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget. 2018 May 25;9 (40) :25833-25841. |[3]Diane Boucher, et al. Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. Cancer Res (2016) 76 (14_Supplement) : 3716.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  Phase 1

• CAS Number :

  [1476074-39-1]